Compare Mesoblast Limited (MESO) vs Microsoft (MSFT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Microsoft — how do they compare? Mesoblast Limited trades at $16.36 (market cap $2.17B), while Microsoft trades at $398.36 (market cap $2.99T). The key difference: Microsoft is far larger — about 1377.9× Mesoblast Limited's market cap, and Microsoft pays a 0.9% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| MESO | MSFT | |
|---|---|---|
Market Cap | $2.17B | $2.99T |
Sector | Technology | Technology |
52-Week High | $20.96 | $542.07 |
52-Week Low | $12.88 | $352.83 |
Enterprise Value | $2.17B | $2.97T |
Volume | — | 36,654,621 |
Dividend Yield | — | 0.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
Microsoft (MSFT) trades at $398.48, up 1.18% today, with a bullish technical signal and strong fundamentals. The stock shows consistent earnings beats, with Q1 2026 EPS of $4.27 exceeding the $4.06 estimate. Revenue growth is robust, rising to $281.72B in 2025, while net income margins expanded to 36.14%. Analyst sentiment remains overwhelmingly positive, with 80.49% recommending Buy and a consensus price target of $546.70. Recent news highlights AI leadership and Azure momentum, though capital expenditure concerns linger.
Outlook: MSFT's AI integration and cloud dominance support long-term growth, but elevated valuations and competitive pressures pose risks. Investment opportunity lies in sustained earnings momentum and market share gains, while risks include macroeconomic volatility and execution challenges in high-spend initiatives. The stock's current level near pivot point resistance requires monitoring for breakout confirmation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Microsoft
Microsoft Corporation develops, manufactures, licenses, sells, and supports software products. The Company offers operating system software, server application software, business and consumer applications software, software development tools, and Internet and intranet software. Microsoft also develops video game consoles and digital music entertainment devices.
Read more on MSFT →
